ARK Invest Doubles Down on Disruptive Tech with WeRide and GeneDx Bets

Cathie Wood's ARK Investment Management made decisive moves in autonomous transportation and genomics this week. The firm acquired $1.66 million in WeRide Inc. shares through its ARKQ ETF, totaling 858,295 American Depositary Shares over three sessions. This strategic accumulation signals conviction in China's autonomous driving sector despite recent regulatory hurdles.

Simultaneously, ARK purchased $3.81 million worth of GeneDx Holdings Corp stock, maintaining its thematic focus on DNA sequencing's healthcare potential. The buys come alongside portfolio pruning—ARK shed $3.58 million in Iridium Communications exposure and trimmed positions in Ibotta and Roku.

Wood's investment thesis remains clear: bet big on technological convergence. The WeRide purchase complements existing autonomous vehicle holdings like Tesla, while GeneDx aligns with ARKG's genomics mandate. These moves occur as ARK's flagship funds show renewed inflows after 2024's volatility.